Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4404
Peer-review started: July 31, 2021
First decision: September 5, 2021
Revised: September 9, 2021
Accepted: March 25, 2022
Article in press: March 25, 2022
Published online: May 16, 2022
Processing time: 285 Days and 20.8 Hours
The incidence of pancreatic cancers has increased rapidly in recent years in China, with the low survival rate.
The differences in the age, sex and regional distributions of pancreatic cancers are unknown.
To describe the epidemiological trends of pancreatic cancer in China and to conclude the international differences in distributions of pancreatic cancers between the world.
Several datasets are used to demonstrate the epidemiological trends of pancreatic cancers in China from 2006 to 2015. Linear regression models were used to estimate the morbidity and mortality of pancreatic cancers in China in 2025.
The incidence rate of pancreatic cancers increased from 3.65 per 100,000 to 4.31 per 100000 in 2015 and was estimated to rise up to 5.52 per 100000 in 2025. The mortality of pancreatic cancers increased from 3.35 per 100000 to 3.78 per 100000 in 2015 and was estimated to rise up to 4.6 per 100000 in 2025. The age distribution of pancreatic cancer was concentrated after 45 years and especially between 85 and 89 years. The incidence and mortality rates of pancreatic cancers are generally higher in men than in women, and China's are generally higher than the world average. Additionally, disability-adjusted life years attributed to pancreatic cancer in China were 197.22 years per 100000, above the average level of around the world.
The incidence and mortality rates of pancreatic cancers all around the world have been increasing rapidly. Efforts need to be made according to differences in age, sex, regional and international distributions of pancreatic cancers.
The prognosis of pancreatic cancers is so poor that the mortality is close to the morbidity around the world. Modification of high-risk factors, further basic research, multidisciplinary advances in imaging and international collaborations are necessary to implement to prevent pancreatic cancer and to improve prognosis.